PET/CT with 18F-choline after radical prostatectomy in patients with PSA ≤2 ng/ml. Can PSA velocity and PSA doubling time help in patient selection?

2016 ◽  
Vol 43 (8) ◽  
pp. 1418-1424 ◽  
Author(s):  
Agostino Chiaravalloti ◽  
Daniele Di Biagio ◽  
Mario Tavolozza ◽  
Ferdinando Calabria ◽  
Orazio Schillaci
Keyword(s):  
Radical Prostatectomy ◽  
Patient Selection ◽  
Doubling Time ◽  
Psa Doubling Time ◽  
Pet Ct ◽  
Psa Velocity

Influence of PSA, PSA velocity and PSA doubling time on contrast-enhanced 18F-choline PET/CT detection rate in patients with rising PSA after radical prostatectomy

2012 ◽  
Vol 39 (4) ◽  
pp. 589-596 ◽  
Author(s):  
Orazio Schillaci ◽  
Ferdinando Calabria ◽  
Mario Tavolozza ◽  
Cristiana Ragano Caracciolo ◽  
Enrico Finazzi Agrò ◽  
...  
Keyword(s):  
Radical Prostatectomy ◽  
Detection Rate ◽  
Doubling Time ◽  
Choline Pet ◽  
Psa Doubling Time ◽  
Contrast Enhanced ◽  
Pet Ct ◽  
Psa Velocity

865: Comparison of Preoperative PSA Velocity or PSA Doubling Time as a Predictor of Outcome after Radical Prostatectomy

2006 ◽  
Vol 175 (4S) ◽  
pp. 279-279
Author(s):  
Stacy Loeb ◽  
Xiaoying Yu ◽  
Kimberly A. Roehl ◽  
Robert B. Nadler ◽  
Theresa Graif ◽  
...  
Keyword(s):  
Radical Prostatectomy ◽  
Doubling Time ◽  
Psa Doubling Time ◽  
Psa Velocity

950: Pre-Operative PSA Doubling Time is More Powerful than PSA or PSA Velocity as a Predictor of Post Radical Prostatectomy Outcomes

2005 ◽  
Vol 173 (4S) ◽  
pp. 257-257 ◽  
Author(s):  
Shomik Sengupta ◽  
Jeffrey M. Slezak ◽  
Eric J. Bergstralh ◽  
Bradley C. Leibovich ◽  
Robert P. Myers ◽  
...  
Keyword(s):  
Radical Prostatectomy ◽  
Doubling Time ◽  
Psa Doubling Time ◽  
Psa Velocity

PSA and PSA Kinetics as Predictors for 18F-Fluciclovine PET/CT Positivity in Biochemically Recurrent Prostate Cancer

2021 ◽  
pp. 1-8
Author(s):  
Fabio Crocerossa ◽  
Umberto Carbonara ◽  
Jayashree Parekh ◽  
Alfredo Urdaneta ◽  
Samuel Weprin ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Sequential Analysis ◽  
Doubling Time ◽  
Alternative Hypothesis ◽  
Imaging Techniques ◽  
Psa Kinetics ◽  
Psa Doubling Time ◽  
Pet Ct ◽  
Wide Range ◽  
Psa Velocity

<b><i>Introduction:</i></b> <sup>18</sup>F-Fluciclovine PET/CT is one of the imaging techniques currently employed to restage prostate cancer (PCa). Due to the conflicting results reported in the literature, it is not yet known at what PSA threshold <sup>18</sup>F-fluciclovine PET/CT could reliably demonstrate the presence of recurring disease. We explored the association between <sup>18</sup>F-fluciclovine PET/CT positivity and prescan PSA, PSA doubling time, and PSA velocity in patients with biochemical recurrence (BCR) of PCa after curative-intent treatment. <b><i>Methods:</i></b> Data from 59 patients who underwent <sup>18</sup>F-fluciclovine PET/CT for BCR after radical prostatectomy or radiotherapy were retrieved from a single institution database. Patients already undergone salvage treatments at the time of PET/CT, with newly diagnosed PCa or with initial diagnosis of metastatic PCa were excluded. A 2-sided independent samples Bayesian <i>t</i> test and Bayesian Mann-Whitney U test were used to assess the association between PET/CT and prescan PSA, PSA doubling time, and PSA velocity. <b><i>Results:</i></b> Evidence for no difference between PET/CT-positive and -negative patients for log-transformed PSA was found (BF<sub>01</sub> 3.61, % error: 0.01). Robustness check and sequential analysis showed stability across a wide range of prior distribution specifications. The hypothesis of no difference in terms of PSA-dt and for PSA-vel between groups was found to be more likely compared to the alternative hypothesis (BF<sub>01</sub> of 3.44 and 3.48, respectively). <b><i>Conclusion:</i></b> PSA and PSA kinetics are unlikely to be associated with <sup>18</sup>F-fluciclovine PET/CT positivity in patients with BCR, and none of these serum biomarkers might be used as single predictors of PET/CT detection. Larger studies might be needed to evaluate the role of different predictors.

PSA doubling time for prediction of [11C]choline PET/CT findings in prostate cancer patients with biochemical failure after radical prostatectomy

2010 ◽  
Vol 37 (6) ◽  
pp. 1106-1116 ◽  
Author(s):  
Giampiero Giovacchini ◽  
Maria Picchio ◽  
Vincenzo Scattoni ◽  
Rita Garcia Parra ◽  
Alberto Briganti ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radical Prostatectomy ◽  
Cancer Patients ◽  
Doubling Time ◽  
Biochemical Failure ◽  
Choline Pet ◽  
Psa Doubling Time ◽  
Ct Findings ◽  
Pet Ct

PSA Doubling Time as a Predictor of the Outcome of Random Prostate Biopsies Prompted by Isolated PSA Elevation in Subjects Referred to an Outpatient Biopsy Facility in a Routine Clinical Scenario

2008 ◽  
Vol 23 (3) ◽  
pp. 187-191 ◽  
Author(s):  
S. Ciatto ◽  
T. Rubeca ◽  
F. Martinelli ◽  
G. Pontenani ◽  
C. Lombardi ◽  
...  
Keyword(s):  
Multivariate Analysis ◽  
Doubling Time ◽  
Digital Rectal Examination ◽  
Consecutive Series ◽  
Prostate Biopsies ◽  
Psa Doubling Time ◽  
Psa Velocity ◽  
Sextant Biopsy ◽  
Independent Association ◽  
Total Psa

Aim To assess the validity of PSA doubling time (PSADT) as a predictor of prostate sextant biopsy outcome in patients with PSA levels in the 4–10 ng/mL range. Material and methods A consecutive series of 355 sextant biopsies performed during 2001–2007 in subjects with negative digital rectal examination and transrectal ultrasonography was considered. Variables tested as possible predictors were age, total and free/total PSA value, PSA velocity and PSA doubling time. While PSA at time of biopsy and free/total PSA were determined with a standardized method undergoing strict quality control, previous PSA values used to assess velocity/doubling time came from other labs using different assays over widely varying intervals of time. The association with biopsy outcome (cancer vs non-cancer) was investigated by univariate and multivariate analysis. Results Apart from free/total PSA ratio, no other studied variable showed a statistically significant and independent association with biopsy outcome, either at univariate or multivariate analysis. No studied variable had a good performance as a biopsy indicator. Depending on the variable considered, 1.17 to 1.97 cancers would be missed to spare 10 benign biopsies. Conclusion When based on PSA data determined with different assays over widely varying intervals and in the absence of an underlying protocol for PSA surveillance, PSA velocity and doubling time should never discount a biopsy prompted by total PSA elevation.

Prediction of Response to Salvage Radiation Therapy in Patients With Prostate Cancer Recurrence After Radical Prostatectomy

2001 ◽  
Vol 19 (4) ◽  
pp. 1030-1039 ◽  
Author(s):  
Angelos K. Leventis ◽  
Shahrokh F. Shariat ◽  
Michael W. Kattan ◽  
E. Brian Butler ◽  
Thomas M. Wheeler ◽  
...  
Keyword(s):  
Multivariate Analysis ◽  
Radiation Therapy ◽  
Radical Prostatectomy ◽  
Local Recurrence ◽  
Doubling Time ◽  
Salvage Radiation Therapy ◽  
Psa Relapse ◽  
Psa Doubling Time ◽  
Prostatic Fossa ◽  
Biopsy Confirmation

PURPOSE: To identify factors predictive of local recurrence as defined by a complete response to salvage radiation therapy in patients whose disease recurs after radical prostatectomy. PATIENTS AND METHODS: Ninety-five patients with recurrence after radical prostatectomy who were evaluated by prostatic fossa biopsies, and a subset of 49 of these patients treated with radiation for control of presumed or biopsy-proven local recurrence, were studied. RESULTS: Biopsies were positive in 40 (42%) of the 95 biopsied patients. Multivariate analysis revealed that prebiopsy prostate-specific antigen (PSA) level, postrecurrence PSA doubling time, and positive digital rectal examination (DRE) of the prostatic fossa were all statistically significant predictors of a positive biopsy. For the 49 patients subsequently treated with salvage radiation therapy, the overall actuarial 3- and 5-year PSA relapse-free probabilities were 43% and 24%, respectively. Univariate analysis showed no differences in the PSA relapse-free probabilities associated with any pathologic features of the radical prostatectomy specimen, biopsy confirmation of local recurrence, or DRE of the prostatic fossa. In multivariate analysis, controlling for all other variables, preradiation PSA and postrecurrence PSA doubling time measured before radiation were the only statistically significant predictors of outcome. CONCLUSION: DRE of the prostatic fossa, prebiopsy PSA, and postrecurrence PSA doubling time predict which patients will have biopsy-proven local recurrence. However, response to salvage radiation therapy is associated with postrecurrence PSA doubling time and with preradiation PSA level only. DRE of the prostatic fossa and biopsy confirmation of local recurrence are not associated with salvage radiation outcome.

Sign in / Sign up

Export Citation Format

Share Document